IDiyas

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Robert Theodore Vasileff

USPTO Granted Patents = 13

Average Co-Inventor Count = 4.8

ph-index = 9

Forward Citations = 151(Granted Patents)


Company Filing History:

goldMedal13 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 1983-2004

Loading Chart...
13 patents (USPTO):Explore Patents
1. 6713645 - Substituted tricyclics (2004-03-30),
2. 6472405 - Glycoprotein IIB/IIIA antagonists (2002-10-29),
3. 6448269 - Glycoprotein IIb/IIIa antagonists (2002-09-10),
4. 6177440 - Substituted tricyclics (2001-01-23),
5. 6137002 - Glycoprotein IIb/IIIa antagonists (2000-10-24),
6. 6020362 - Glycoprotein IIB IIIA antagonists (2000-02-01),
7. 6013674 - Cell adhesion inhibitors (2000-01-11),
8. 5731324 - Glycoprotein IIb/IIIa antagonists (1998-03-24),
9. 5618843 - Glycoprotein IIb/IIIa antagonists (1997-04-08),
10. 4888100 - Photochemical conversion of cephalosporins, (1989-12-19),
11. 4577014 - Thieno and furopyridinium-substituted cephalosporins (1986-03-18),
12. 4501739 - Thieno and furopyridinium-substituted cephalosporins (1985-02-26),
13. 4406898 - Oxazole and oxadiazole cephalosporins (1983-09-27),

Title: The Innovative Contributions of Robert Theodore Vasileff

Introduction

Robert Theodore Vasileff is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 13 patents. His work focuses on developing novel compounds that have the potential to treat various medical conditions.

Latest Patents

Among his latest patents, Vasileff has developed a class of novel tricyclics aimed at inhibiting sPLA mediated release of fatty acids. This innovation is particularly relevant for treating conditions such as septic shock. Additionally, he has created glycoprotein IIB/IIIA antagonists, which are bicyclic compounds useful in inhibiting platelet aggregation. These compounds feature a nucleus formed of two fused six-membered rings, such as isoquinoline and tetrahydronaphthalene, and are substituted with both basic and acidic functionalities.

Career Highlights

Vasileff is currently associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation in healthcare. His work at Eli Lilly has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout his career, Vasileff has collaborated with notable colleagues, including John Michael Morin, Jr. and Michael Dean Kinnick. These collaborations have further enhanced the impact of his inventions and research.

Conclusion

Robert Theodore Vasileff's innovative work in pharmaceuticals has led to significant advancements in medical treatments. His contributions continue to influence the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…